Table 3.
Distribution of Study Uropathogens at Baseline
| Uropathogens by Study Population | Sulopenem n (%) |
Ciprofloxacin n (%) |
|---|---|---|
| mMITT-R | ||
| ȃNumber of patients | 147 | 139 |
| ȃNumber of organisms | 154 | 144 |
| ȃȃEscherichia coli | 127 (86.4) | 120 (86.3) |
| ȃȃKlebsiella pneumoniae | 14 (9.5) | 16 (11.5) |
| ȃȃProteus mirabilis | 9 (6.1) | 6 (4.3) |
| ȃȃMorganella morganii | 3 (2.0) | 1 (0.7) |
| ȃȃEnterobacter cloacae complex | 1 (0.7) | 0 (0.0) |
| ȃȃProvidencia stuartii | 0 (0.0) | 1 (0.7) |
| mMITT-S | ||
| ȃNumber of patients | 370 | 415 |
| ȃNumber of organisms | 381 | 430 |
| ȃȃEscherichia coli | 313 (84.6) | 349 (84.1) |
| ȃȃKlebsiella pneumoniae | 37 (10.0) | 32 (7.7) |
| ȃȃProteus mirabilis | 8 (2.2) | 11 (2.7) |
| ȃȃStaphylococcus saprophyticus | 5 (1.4) | 8 (1.9) |
| ȃȃKlebsiella aerogenes | 4 (1.1) | 6 (1.4) |
| ȃȃCitrobacter freundii | 0 (0.0) | 6 (1.4) |
| ȃȃCitrobacter koseri | 4 (1.1) | 1 (0.2) |
| ȃȃEnterobacter cloacae complex | 3 (0.8) | 2 (0.5) |
| ȃȃKlebsiella oxytoca | 2 (0.5) | 3 (0.7) |
| ȃȃKlebsiella variicola | 4 (1.1) | 1 (0.2) |
| ȃȃLelliottia amnigena | 1 (0.3) | 3 (0.7) |
| ȃȃMorganella morganii | 0 (0.0) | 3 (0.7) |
| ȃȃRaoultella planticola | 0 (0.0) | 2 (0.5) |
| ȃȃEnterobacter aerogenes | 0 (0.0) | 1 (0.2) |
| ȃȃPantoea septica | 0 (0.0) | 1 (0.2) |
| ȃȃSerratia marcescens | 0 (0.0) | 1 (0.2) |
Patients could have more than 1 pathogen.
Abbreviations: mMITT-R, microbiologic modified intent-to-treat with a qualifying baseline urine isolate nonsusceptible to ciprofloxacin; mMITT-S, microbiologic modified intent-to-treat with a qualifying baseline urine isolate susceptible to ciprofloxacin.